
|Videos|July 2, 2013
Episode 2 - Elucidating the Patient's Starting Point in Care
Advertisement
Episodes in this series

The clinical paradigm for multiple sclerosis (MS) has witnessed an important shift in recent years, and those dynamics can be attributed to the advent of disease-modifying therapies (DMTs), increased awareness, and the conceptual evolution of MS becoming a treatable disease that requires early and effective intervention to better control the damage process caused by MS. Admittedly, while more patients with MS may be entering the health system through specialist referrals and neurologists, improved diagnostic modalities, such as the advances in neurology and neuro-imaging via MRI scan, arguably still does not explain the increased incidence of MS, and unfortunately, diagnosis of the disease is still not occurring early enough.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol
2
SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next
3
Stem Cell Transplant Outperforms DMTs in Drug-Resistant Relapsing MS
4
Deep Learning Model Matches Expert Agreement in Sleep Arousal Scoring
5





















